Bicycle therapeutics plc announces new preclinical data from bt7480

Bicycle therapeutics plc announced that new preclinical data from bt7480, a potent tumor-targeted immune cell agonist (tica) targeting nectin-4 and agonizing cd137 (4-1bb), bt7480 has shown very potent and tumor antigen dependent cd137 agonism in ex vivo experiments using patient-derived lung tumor samples that have intact immune microenvironments. in a nectin-4 overexpressing syngeneic tumor model, 92% (n=24) of animals dosed with bt7480 experienced complete tumor regressions. five of the complete responder animals were subsequently re-challenged with the same tumor cell implantation and no tumor growth was observed, implying development of immunogenic memory. in addition to these data on bt7480, the company will also present preclinical data at sitc on other emergent bicycle tica strategies.
BCYC Ratings Summary
BCYC Quant Ranking